PsoriasisDiagnostics and screeningDiagnostic test
What this study is
Psoriasis is a chronic and recurrent skin disorder characterized by marked inflammatory changes in the skin. An extensive cytokine network including generated by activated dendritic cells and T cells mediates the formation of psoriatic lesions. These immune-response parameters can be used as markers in the severity and management of the disease after further in-depth studies.
What's being tested
- Inflammatory markers
Intervention · DIAGNOSTIC TEST
Study details
- Sponsor
- University of Alabama at Birmingham
- Conditions
- Psoriasis · Inflammation
- Enrolling
- 13 people
- Starts
- 2014-04-22
- Est. completion
- 2028-04-28
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 19 Years – 99 YearsSex ALLHealthy volunteers AcceptedYou may qualify if
- Clinical diagnosis of psoriasis
- Must be age 19 or older.
- Must be Fitzpatrick skin type I, II, III, IV, V, VI.
You can't join if
- Subjects who do not have photosensitive disease and are not on photosensitizing medications.
- Subjects with a history of keloids (who are more likely to develop hypertrophic scars following skin biopsy).
- Subjects who have an allergy to local anesthetics, antibiotics and/or anticoagulants.
- Subjects who are pregnant.
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
1
Study locations (1)
1 openThe Kirklin Clinic
Birmingham, Alabama, United States
- Wendy Cantrell · Contact205 502 9960wcantrell@uabmc.edu
Recruiting
Study team
Sponsor
University of Alabama at Birmingham
Study ID F120628003
Have questions? The record lists no central contact. Use Consider me and the site team can reach you, or find them through ClinicalTrials.gov ↗.
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.